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Abstract Impaired simulated driving performance has
been demonstrated in obstructive sleep apnoea–hypopnoea
syndrome (OSAHS) patients. Although continuous positive
airway pressure (CPAP) generally improves simulated
driving performance, the effects of oral-appliance (OA)
therapy are unknown. The aims of this study were to
determine to what extent OSAHS patients have more
difficulty with a monotonous simulated driving test when
compared with control subjects and to compare the effects
of OA with CPAP therapy. Simulated driving performance
was evaluated in 20 OSAHS patients and 16 control
subjects during a 25-min driving test. After randomization,
ten patients started OA and CPAP therapy, respectively.
After 2 to 3 months of treatment, patients repeated the
driving test. At baseline, the total number of lapses of
attention during driving was significantly higher in OSAHS
patients as compared with control subjects. As a result of
treatment, the total number of lapses of attention was
significantly decreased in both the OA and CPAP group.
When comparing driving performance between the OA and
CPAP group, no significant differences were noted.
OSAHS patients perform worse on a simulated driving test
when compared with control subjects. When evaluating the
effects of treatment, adequate OSAHS management with
either OA or CPAP therapy usually resulted in substantial
improvements of simulated driving. Conclusions beyond
both treatments improving simulated driving performance
are, however, not justified by the data in the present study.
Keywords Sleep apnoea syndromes . Automobile driving .
Orthodontic appliances . Positive-pressure ventilation
Introduction
The obstructive sleep apnoea–hypopnoea syndrome
(OSAHS) is a common sleep-related breathing disorder
associated with serious neurocognitive and cardiovascular
sequelae [1]. In OSAHS patients, respiratory-related
arousals during sleep cause sleep fragmentation and a
depletion of rapid eye movement and slow-wave sleep,
ultimately resulting in excessive daytime sleepiness. Day-
time sleepiness may adversely affect daytime performance
and consequently, among other sequelae, influence driving
performance [2, 3]. Studies evaluating subjective (self-
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reports) or objective (motor vehicle department) records
sustain the opinion that OSAHS confers an increased risk
for accidents when driving [4, 5]. In addition, performance
on driving simulator and vigilance tests of varying
complexity have been shown impaired in OSAHS patients
[6–10]. Driving is a multifaceted and multilevelled skill,
and it is impossible to assess all of its aspects in a simulator
[11]. Depending on the nature of the disorder studied, key
driving tasks can be selected for clinical assessment. In
OSAHS patients, the primary problem is to sustain attention
in monotonous situations. Therefore, the most relevant
driving task is prolonged driving on a monotonous
highway. Most simulator studies in OSAHS patients use a
variation of this task [6–10].
When evaluating the effects of OSAHS treatment on
motor vehicle crash risk, marked improvements are
generally reported. Studies evaluating subjective and
objective records indicate that continuous positive airway
pressure (CPAP) therapy reduces collision and crash
frequency in OSAHS patients [4, 8, 12]. In addition,
successful treatment with CPAP therapy generally results
in improvements of simulated driving performance [13–15].
Similar improvements in simulated driving performance
have been demonstrated after successful OSAHS manage-
ment by means of uvulopalatopharyngoplasty [6]. Over the
past decade, oral-appliance (OA) therapy has emerged as a
well-proven alternative in the treatment of OSAHS patients
that is accepted by the sleep society [16, 17]. An OA aims
at relieving upper airway collapse during sleep by modify-
ing the position of the mandible, the tongue, and pharyn-
geal structures. However, the effects of OA therapy on
simulated driving performance have not been evaluated to
date [16].
The aims of this study were to determine to what extent
OSAHS patients have more difficulty with a monotonous
simulated driving test when compared with control subjects
and to compare the effects of OA with CPAP therapy.
Materials and methods
Patients
Control subjects and a subset of OSAHS patients, recruited
for a randomized trial comparing the effectiveness of OA
and CPAP therapy, comprised the study population. All
subjects were required to be aged between 21 and 70 years,
in the possession of a drivers licence, not involved in shift-
work or night-time work, and otherwise fit to drive.
Thirty consecutive patients who underwent polysomnog-
raphy (baseline polysomnography) and were diagnosed as
having OSAHS with an apnoea–hypopnoea index (AHI)>5
were considered for inclusion in the present study. Patients
were recruited through the Department of Home Mechan-
ical Ventilation of the University Medical Center Groningen
(Groningen, The Netherlands) in the period March to June
2004. Patients were excluded in case of previous OSAHS
treatment, clearly reversible morphological airway abnor-
malities, endocrine dysfunction (one patient with hypothy-
roidism, two patients with pituitary adenoma), a reported or
documented history of severe cardiac or pulmonary disease
(one patient with daytime respiratory insufficiency), mod-
erate or severe periodic limb movement disorder (i.e.
periodic limb movement index >25), or a psychological
condition precluding informed consent. Patients with a
dental status that could complicate OA therapy were also
excluded (three patients had an insufficient number of teeth,
one patient had extensive periodontal disease) [16].
Because two of the remaining 22 patients refused partici-
pation, 20 OSAHS patients could eventually be enrolled.
Sixteen healthy subjects matched for age and without signs
of a neurological or psychiatric disorder were recruited as
control group. The control group comprised a diverse
compilation of hospital employees who had no knowledge
or clinical suspicion by questionnaire analyses of having a
sleeping disorder. The randomized trial was approved by
the Groningen University Medical Center’s ethics commit-
tee (METc 2002/032). Written informed consent was
obtained from each patient before enrolment after full
explanation of the procedure. In addition, all control
subjects consented to participation in the study after full
explanation of the procedure.
Study design
Of the 20 OSAHS patients, ten were allocated to OA
therapy and ten to CPAP therapy by means of block
randomization [18]. OA therapy was initiated in the
Department of Oral and Maxillofacial Surgery and was
supervised by one dentist. CPAP therapy was initiated in
the Department of Home Mechanical Ventilation and was
supervised by one pulmologist. It was not possible to blind
the patients or clinicians to treatment assignment. At
baseline all OSAHS patients and control subjects completed
the Epworth sleepiness scale [19] and an in-house ques-
tionnaire evaluating medication prescription, caffeine con-
sumption, tobacco use, and driving experience. Thereupon,
simulated driving performance was evaluated in both
groups during a 25-min driving test.
The OA used in this study (Thornton Adjustable
Positioner, Airway Management, Dallas, TX, USA) con-
sisted of two separate parts and positioned the patient’s
mandible in a forwards and downwards position [20]. The
upper part was supported by the dentition of the maxilla
and the lower part by the dentition of the mandible. By
turning a propulsion screw incorporated anteriorly in the
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appliance, the patient could adjust the amount of mandib-
ular advancement in 0.2-mm increments. The maximum
advancement of the mandible was determined with a
George-Gauge™ (H-Orthodontics, Michigan City, IN,
USA) before OA therapy began. Initially, the mandible
was set at approximately 50% of the patient’s maximum
advancement. After patients became accustomed to the OA
during a 2-week period, they returned for a check-up visit.
They were instructed to adjust the OA over the following
6 weeks. To do so, patients were instructed to advance the
mandible each night with one to two increments (i.e. 0.2 to
0.4 mm) whenever OSAHS-symptomatology persisted (e.g.
snoring, apnoeas, hypopnoeas, or excessive sleepiness).
This titration of the appliance was continued until symp-
toms abated or until further advancement of the mandible
caused discomfort.
CPAP titration was performed during an afternoon nap.
This technique, aimed at abolishing all signs of apnoea,
hypopnoea, and snoring, has been shown an appropriate
procedure for the effective titration of CPAP [21]. After
titration, an 8-week follow-up period was arranged that
allowed for habituation and, if necessary, adjustments of
CPAP therapy.
After patients used an OA or CPAP for 8 weeks, the
treatment effect was assessed with a second polysomno-
graphic study. For patients whose AHI was still ≥5,
treatment was adjusted, if possible, to improve effective-
ness. For this purpose OA-treated patients were instructed
to protrude their mandible with the appliance to the
maximum point of protrusion, which was still comfortable
during a full therapeutic night. In CPAP-treated patients, the
pressure was raised by the pulmologist supervising therapy
with 1 or 2 cm H2O (depending on the severity of residual
OSAHS with CPAP). In these patients, the follow-up period
was extended with another 4 weeks. The effect was then
assessed with a third polysomnographic study. This
adjustment sequence was continued until the AHI was
<5 or until the adjustments became uncomfortable for the
patient. Follow-up review ended with a patient’s final
polysomnographic evaluation or when a patient discontin-
ued treatment because of poor tolerance or another reason.
At their final follow-up review, patients again completed the
Epworth sleepiness scale and driving test performed at
baseline. In addition, treatment usage was evaluated at this
stage by asking patients how many nights per week and
how many hours per night they used their treatment.
Treatment was considered effective when the AHI either
was <5 or showed “substantial reduction” [16], defined as
reduction in the index of at least 50% from the baseline
value to a value of <20 in a patient who had no symptoms
while using therapy. Patients not meeting these criteria at
their final review were considered “nonresponsive” to
treatment.
Polysomnography
Polysomnography (Embla® A10 digital recorder, Medcare,
Reykjavik, Iceland) for baseline and follow-up evaluations
was conducted ambulatory in the patient’s home situation.
Each study started 11 A.M. and stopped 9 A.M. the next
morning. Surface electroencephalography, submental elec-
tromyography, and left and right electrooculography were
used to stage sleep. A pulsoximeter (Oximeter Flex Sensor–
8000J-3, Medcare) was used to record oxyhaemoglobin
saturation. Electrocardiography was used to monitor cardiac
function. Oronasal airflow was recorded with a pressure
cannula. Respiratory effort was monitored with thoracic and
abdominal strain gauges. An anterior tibial electromyogram
was recorded to screen for periodic limb movements.
Outcomes were limited to the time in bed part of the
study. Standardized criteria were used to score apnoeas
and hypopnoeas [22], arousals [23], sleep stages [24], and
periodic limb movements [25]. All polysomnographic
studies were evaluated and scored by one neurophysiolo-
gist (J.H.) who was unaware of the patient’s treatment
assignment.
Driving simulator
The driving test was performed on the driving simulator of
the Department of Neuropsychology [26, 27]. All subjects
were tested between noon and 2 P.M. In OSAHS patients,
the second driving test was conducted at the same point of
time as the first evaluation. Instructions were to refrain
from stimulating products (e.g. caffeine) 3 h before testing
and not to smoke half an hour before testing. To keep
testing conditions as consistent as possible lights were
dimmed, noise was shut out, and room temperature was
kept at 22°C. The driving test had to be completed in
absence of company, including the test leader (M.B.).
Subjects were seated in a comfortable office chair behind a
21-in. computer screen on which the scene of a straight
road was projected. Using a computer game steering wheel,
the lateral position on this road could be controlled. In
all conditions, the speed of driving was fixed at 50 km/h,
and the only objective was to drive as straight as possible
in the middle of the right lane, while compensating for
the effect of a low amplitude unpredictable “side-wind”
signal (superposition of 1/15, 1/7.5, and 1/3.75 Hz
sinusoids). Because of this unpredictable “side wind”,
subjects had to stay alert continuously to accomplish the
task without getting out of lane. After a 5-min practice, it
was ascertained that subjects had mastered the task. Sub-
sequently, all subjects performed a 25-min driving test in
a monotonous situation. Side-wind amplitude was set low
so that all subjects could easily perform the task in the
first 5 min, showing standard deviations of lateral position
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comparable to straight road driving in “the real world”
[28].
During the test, every 15 s, the standard deviation of the
lateral position (SDLP) was calculated. Driving perfor-
mance was expressed in two separate parameters:
– The number of lapses of attention (LOA). For this
purpose, the median of 20 consecutive SDLP’s was
computed, resulting in one number every 5 min.
Subjects were considered to perform at a normal level
during the first five test minutes, unaffected yet by the
monotonous task. A lapse of attention was defined as a
SDLP in a given 15-s period that was twice as high as
the median SDLP of the first five test minutes.
– The time course SDLP to assess a possible individual
increase in the five median SDLP’s. For this purpose,
an individual linear regression analysis was computed
of the five consecutive median SDLP’s, resulting in a
slope coefficient. The higher this number, the steeper
the regression line and the larger the adverse effect of
time on simulated driving performance.
Analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences version 12.0 (SPSS,
Chicago, IL, USA). Means and standard deviations or
medians and interquartile ranges in skewed distributions are
reported. The total number of LOA during the driving test
was used as primary outcome measure. Other driving test
outcomes included the number of LOA per 5-min time
stage (five epochs) and the slope coefficient of time course
SDLP. To compare outcomes between the groups, indepen-
dent sample t-tests were used (Mann–Whitney U tests for
variables with skewed distributions). Differences between
baseline and follow-up variables in the OA and CPAP
groups were compared with paired Student’s t-tests
(Wilcoxon’s signed ranks tests for variables with skewed
distributions). To measure correlations in the OSASHS
group between the total number of LOA, AHI, and Epworth
sleepiness scale, Spearman’s rank correlation coefficients
were calculated. A significance level of p<0.05 was
predefined in all cases.
Results
OSAHS patients vs control subjects
When comparing the 20 OSAHS patients and the 16 control
subjects, no significant differences in age, daily caffeine
and nicotine consumption, or driving experience were
observed at baseline (Table 1). With respect to the Epworth
sleepiness scale, a significantly higher level of subjective
sleepiness was observed in the OSAHS patient group.
Before treatment, driving performance, as indicated by
the total number of LOA, was worse in OSAHS patients
than in control subjects (Table 2, Fig. 1). In addition, there
were significantly more LOA’s in the second to the fifth
epoch in OSAHS patients than in the control subjects. The
slope coefficient of the time course of SDLP significantly
differed in favour of the control subjects. In the OSAHS
patients, no significant correlation was observed between
the total number of LOA and the AHI or the Epworth
sleepiness scale.
Effects of OA and CPAP therapy
Of the ten patients that were allocated to OA therapy, one
patient’s symptoms and driving performance deteriorated
(increase in the total number of LOA from 17 to 26) due to
a severe periodic limb movement syndrome at final follow-
up review (increase in periodic limb movement index from
0 to 62). This deterioration after treatment could not be
explained by a residual OSAHS (reduction AHI from 28 to
0) nor were there any other factors that could explain this
phenomenon (e.g. anthropometry or driving experience).
This patient was, therefore, excluded from further analysis.
Baseline characteristics were similar for the nine OA- and
ten CPAP-treated patients (Table 3). At final review, the
mean advancement of the mandible with the OA was 89±
23% of the maximum advancement. The mean CPAP
pressure was 8.7±2.2 cm H2O at final review. The median
period to final review was 81 (interquartile range 72–93)
days in the OA group and 79 (interquartile range 63–102)
days in the CPAP group (p>0.05).
Treatment was effective for eight patients in the OA
group and for nine patients in the CPAP group. The two
remaining patients were “nonresponsive” to treatment. As a
result of OA and CPAP therapy, the AHI and MinSaO2
improved significantly in both groups (Table 3). No
significant differences in the AHI and MinSaO2 were found
between the treatment groups at final follow-up review. The
Epworth sleepiness scale was significantly improved only
in the CPAP-treated group. When comparing Epworth
sleepiness scale values at final review, no significant
differences were noted between the two groups. There
were no significant differences between the treatment
modalities with regard to usage (Table 3).
No significant differences in driving performance were
observed between the two groups at baseline (Table 4).
After therapy, the total number of LOA was significantly
decreased in both groups. In one OA- and one CPAP-
treated patient, the total number of LOA was increased at
final follow-up review (Fig. 1). Both patients were
“nonresponsive” to treatment. Significant improvements in
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the remaining driving test outcomes were observed only in
the CPAP group for the number of LOA in the fifth
epoch. No significant differences were noted between the
driving test data at final review for OA and CPAP therapy.
For the OSAHS patient group, a significant correlation
was demonstrated between changes in the total number
of LOA and the Epworth sleepiness scale after treatment
(r=0.570, p=0.01).
Discussion
This study shows that OSAHS patients clearly have
difficulty with a simulated driving test when compared
with control subjects. During the 25-min driving test,
OSAHS patients showed a considerable deterioration in
simulated driving performance. When evaluating the effects
of OA and CPAP treatment on driving performance,
significant improvements in the total number of lapses of
attention were observed in both treatment groups. These
findings suggest that effective OSAHS treatment, with
either OA or CPAP therapy, contributes to an improvement
of simulated driving performance.
Based on the total number of LOA, OSAHS patients
show worse driving performance when compared with
control subjects. These findings are in keeping with other
studies that also showed impaired performance in OSAHS
patients during various tests of simulated driving [7, 9, 10].
The present study also suggests that simulated driving
performance in OSAHS patients deteriorates with time on
task, as indicated by the slope coefficient of the time course
SDLP. Because already in the second epoch significantly
more LOA occurred in the OSAHS group, a decline in
driving performance may be expected after a relatively
short period of time (i.e. 10 min). In contrast to several
other simulator studies [2], the present study only evaluated
Table 2 Baseline driving test outcomes for OSAHS patients and control subjects
Variable OSAHS patients (n=20)a Control subjects (n=16)a Differenceb
Number of LOA
Total (0–25 min) 10.0 (1.3–14.5) 0.0 (0.0–1.8) p=0.000
First epoch (0–5 min) 0.0 (0.0–0.0) 0.0 (0.0–0.0) NS
Second epoch (6–10 min) 0.0 (0.0–1.0) 0.0 (0.0–0.0) p=0.021
Third epoch (11–15 min) 1.0 (0.0–4.8) 0.0 (0.0–0.0) p=0.005
Fourth epoch (16–20 min) 3.0 (0.3–5.8) 0.0 (0.0–0.0) p=0.000
Fifth epoch (21–25 min) 2.5 (0.0–6.0) 0.0 (0.0–0.0) p=0.001
Slope coefficient of time course SDLP 0.41 (0.06–0.70) 0.03 (−0.15–0.17) p=0.006
LOA lapses of attention; NS not significant; OSAHS obstructive sleep apnoea–hypopnoea syndrome; SDLP standard deviation of the lateral
position
a Values with additives in parenthesis are medians with interquartile ranges.
b Significance for the difference in baseline driving test outcomes between the OSAHS patients and control subjects.
Table 1 Baseline characteristics for OSAHS patients and control subjects
Variable OSAHS patients (n=20)a Control subjects (n=16)a Differenceb
Male/female ratio 17/3 13/3 –
Age (year) 48.7±11.2 48.7±10.0 NS
BMI (kg/m2) 33.2±5.7 – –
Neck circumference (cm) 44.2±2.7 – –
Epworth sleepiness scale 13.5±6.5 6.1±4.3 p=0.000
Caffeine (units/day) 5.5±3.3 6.7±3.4 NS
Nicotine (units/day) 0.0 (0.0–9.5) 0.5 (0.0–12.5) NS
Driving experience
Years of driving experience 29±10 29±11 NS
Annual number of kilometres×103 15 (10–32) 13 (6–20) NS
AHI (events/hour) 49.1±33.3 – –
MinSaO2 (%) 76.4±9.7 – –
AHI apnoea–hypopnoea index; BMI body mass index; NS not significant; MinSaO2 lowest oxyhaemoglobin saturation during sleep; OSAHS
obstructive sleep apnoea–hypopnoea syndrome
a Plus–minus values are means±standard deviations, values with additives in parenthesis are medians with interquartile ranges.
b Significance for the difference in baseline characteristics between the OSAHS patients and control subjects.
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primary vehicle control. Secondary tasks, such as reaction
time to specific stimuli, have been shown to actually
stimulate drivers when performing a simulator test [29].
Because the driving test used in the present study proved to
be sensitive to distinguish OSAHS patients from controls, it
appears a valid measure of the fatiguing effects of a
monotonous task.
Despite the fact that OSAHS patients performed worse
as a group, not all patients showed impaired simulator
performance when compared with the control subjects. This
variability in simulated driving performance has also been
observed in previous studies [7, 9, 13]. In the present study,
this phenomenon may be explained by inclusion of OSAHS
patients of varying severity. However, at baseline, signifi-
cant correlations between the total number of LOA and the
AHI or Epworth sleepiness scale could not be demonstrat-
ed. These findings are corroborated by other studies that
also fail to demonstrate strong relationships between these
parameters and driving simulator performance [7, 10].
Therefore, the question remains as to what extent other
factors, besides OSAHS severity and symptoms, affect
sustained driving performance in untreated patients (e.g.
personality or coping strategies).
Especially in the case of a more deviant performance at
baseline, adequate OSAHS management by means of either
OA or CPAP therapy usually resulted in substantial
improvements of simulated driving. The correlation ob-
served between changes in the total number of LOA and
Epworth sleepiness scale values suggests that adequate
OSAHS management ameliorates driving performance.
This suggestion is supported by the fact that worse driving
performance at the final review was observed in those
patients who were “nonresponsive” to OA or CPAP
therapy. Other studies evaluating simulator performance
after CPAP therapy or uvulopalatopharyngoplasty usually
also observe improvements in driving performance [6, 13–
Fig. 1 Individual values of the
total number of LOA in OSAHS
patients and control subjects. In
OSAHS patients, the total num-
ber of LOA at baseline and final
follow-up review are depicted
according to treatment group
(i.e. OA or CPAP). The total
number of LOA are not depicted
for one patient allocated to OA
therapy. This patient was ex-
cluded from follow-up analysis
because his symptoms and driv-
ing performance deteriorated
due to a severe periodic limb
movement syndrome at the final
follow-up review (increase in
periodic limb movement index
from 0 to 62). At baseline, the
total number of LOA for this
patient was 17
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15, 30]. To our knowledge, the present study is the first to
study the effects of OA therapy on simulated driving
performance. Although both groups showed significant
improvements in the total number of LOA, significant
improvements for the number of LOA in the fifth epoch
were observed only for the subjects treated with CPAP.
These findings may suggest a more pronounced effect of
CPAP therapy on simulated driving performance. However,
it is more likely that methodological issues explain this
phenomenon. First, our study was of explorative character
and not based on a power calculation. Second, despite non-
significant differences, baseline values indicated more
severe OSAHS and worse simulator performance in the
CPAP group. In addition, with respect to baseline and
follow-up values, no significant differences in simulated
driving performance could be demonstrated between
CPAP- and OA-treated patients.
Despite the observed differences with control subjects
and the favourable effects of treatment on simulator
performance, there are a number of limitations to the
present study. The first limitation refers to the control
group. Control subjects were hospital employees and
approximately 70% agreed after being asked to participate.
Therefore, selection bias may have occurred. In addition,
because polysomnographic data were not available in this
group, subjects with “sub-clinical” OSAHS may have been
included. However, questionnaire analyses raised no evi-
dence of OSAHS symptoms in the control subjects.
Table 3 Baseline and follow-up characteristics for OA- and CPAP-treated patients
Variable OA (n=9)a CPAP (n=10)a Differenceb
Male/female ratio 7/2 9/1 –
Age (year) 47.6±11.0 49.7±12.4 NS
BMI (kg/m2)
Baseline 32.5±6.6 34.2±5.2 NS
Neck circumference (cm)
Baseline 43.3±3.1 45.0±2.4 NS
Epworth sleepiness scale
Baseline 11.3±7.9 15.0±5.0 NS
Follow-up reviewc 6.7±6.0 5.5±4.1 NS
Δ −4.7±7.7 −9.5±6.6***** NS
Caffeine (units/day)
Baseline 6.2±3.6 5.1±3.2 NS
Nicotine (units/day)
Baseline 0.0 (0.0–7.0) 0.0 (0.0–8.5) NS
Driving experience
Years of driving experience 28±9 30±12 NS
Annual number of kilometres×103 15 (5–23) 18 (10–50) NS
AHI (events/hour)
Baseline 47.7 (12.0–92.6) 54.6 (22.8–65.1) NS
Follow-up reviewc 5.3 (0.2–9.9) 0.0 (0.0–4.8) NS
Δ −42.5 (−68.8 to −12.0)** −54.6 (−64.9 to −16.2)**** NS
Min SaO2 (%)
Baseline 78.0 (74.0–80.5) 79.5 (66.8–83.3) NS
Follow-up reviewc 91.0 (82.0–92.5) 92.0 (88.0–94.0) NS
Δ 9.0 (6.0–15.0)* 12.5 (9.5–24.3)*** NS
Treatment usage
Nights per week 6.8±0.4 6.8±0.6 NS
Hours per night 7.0±0.9 6.7±1.4 NS
AHI apnoea–hypopnoea index; BMI body mass index; CPAP continuous positive airway pressure; NS not significant; MinSaO2 lowest
oxyhemoglobin saturation during sleep; OA oral appliance
a Plus–minus values are means±standard deviations, values with additives in parenthesis are medians with interquartile ranges.
b Significance for the difference in baseline, follow-up, or Δ outcomes between treatment groups.
c The median treatment period from baseline until final follow-up review was 81 (interquartile range 72–93) days in the OA group and 79
(interquartile range 63–102) days in the CPAP group (p>0.05).
*p=0.01 for difference between baseline and follow-up outcomes within treatment group
**p=0.008 for difference between baseline and follow-up outcomes within treatment group
***p=0.007 for difference between baseline and follow-up outcomes within treatment group
****p=0.005 for difference between baseline and follow-up outcomes within treatment group
*****p=0.001 for difference between baseline and follow-up outcomes within treatment group
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Therefore, based on the definition criteria employed in the
present study [22], the chance of having included patients
with OSAHS in the control group is unlikely. A second
limitation refers to a possible “learning effect” on the
driving simulator when evaluating patients at the final
follow-up review. Previous studies have failed to demon-
strate profound learning effects in simulated driving
performance in OSAHS patients [7, 30]. Our driving
simulator test could easily be performed by all subjects
because the difficulty level was low and subjects were
allowed to master the task during a practice session. If a
learning effect would have been present, it would therefore
have had a limited effect on the performance during the
second driving test. In addition, any residual learning effect
was controlled for between the two treatments through the
use of a parallel study design. Thirdly, changes in simulator
performance may (at least in part) result from a placebo
effect. In addition, simulator performance may be influ-
enced by volition and motivation, which may add further
noise to the observed improvements in simulator perfor-
mance. Trials comparing placebos with therapeutic CPAP,
however, have failed to demonstrate strong placebo effects
with respect to simulated driving performance [14]. A
fourth limitation may be the fact that patient’s reported
treatment usage was not objectified in the present study.
Whereas CPAP usage can be monitored covertly with a
mechanism built into the device, oral-appliance usage
cannot be assessed covertly in any reliable way. To
eliminate bias, we ensured that treatment usage was
assessed in the same manner by basing the assessments
on self-reports in both groups. Questionnaire analysis
indicated adequate treatment usage in both groups. How-
Table 4 Baseline and follow-up driving test outcomes for OA- and CPAP-treated patients
Variable OA (n=9)a CPAP (n=10)a Differenceb
Number of LOA
Total (0–25 min)
Baseline 5.0 (2.0–14.0) 10.0 (1.0–16.8) NS
Follow-up reviewc 0.0 (0.0–2.0) 0.5 (0.0–5.3) NS
Δ −5.0 (−12.5 to −0.5)** −3.0 (−16.0–0.0)** NS
First epoch (0–5 min)
Baseline 0.0 (0.0–1.0) 0.0 (0.0–0.0) NS
Follow-up reviewc 0.0 (0.0–0.5) 0.0 (0.0–0.0) NS
Δ 0.0 (−1.0–0.0) 0.0 (0.0–0.0) NS
Second epoch (6–10 min)
Baseline 0.0 (0.0–1.0) 0.0 (0.0–1.0) NS
Follow-up reviewc 0.0 (0.0–0.0) 0.0 (0.0–0.3) NS
Δ 0.0 (−1.0–0.0) 0.0 (−1.0–0.3) NS
Third epoch (11–15 min)
Baseline 0.0 (0.0–5.0) 1.0 (0.0–2.5) NS
Follow-up reviewc 0.0 (0.0–0.0) 0.0 (0.0–1.0) NS
Δ 0.0 (−4.5–0.0) 0.0 (−1.8–0.3) NS
Fourth epoch (16–20 min)
Baseline 2.0 (0.0–5.5) 3.0 (0.8–7.8) NS
Follow-up reviewc 0.0 (0.0–0.5) 0.0 (0.0–0.5) NS
Δ −2.0 (−5.5–0.0) −1.0 (−7.8–0.0) NS
Fifth epoch (21–25 min)
Baseline 2.0 (0.0–4.0) 4.0 (0.0–8.5) NS
Follow-up reviewc 0.0 (0.0–1.0) 0.0 (0.0–2.5) NS
Δ −1.0 (−3.5–0.0) −2.0 (−8.3–0.0)* NS
Slope coefficient of time course SDLP
Baseline 0.20 (0.06–0.60) 0.63 (0.04–0.90) NS
Follow-up reviewc 0.05 (−0.06–0.30) 0.14 (−0.22–0.28) NS
Δ −0.01 (−0.55–0.13) −0.15 (−1.20–0.23) NS
CPAP continuous positive airway pressure; LOA lapses of attention; NS not significant; OA oral appliance; SDLP standard deviation of the lateral
position
a Plus–minus values are means±standard deviations, values with additives in parenthesis are medians with interquartile ranges.
b Significance for the difference in baseline, follow-up, or Δ outcomes between treatment groups.
c The median treatment period from baseline until final follow-up review was 81 (interquartile range 72–93) days in the OA group and 79
(interquartile range 63–102) days in the CPAP group (p>0.05).
*p=0.04 for difference between baseline and follow-up outcomes within treatment group
**p=0.03 for difference between baseline and follow-up outcomes within treatment group
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ever, self-reports usually overestimate the use of treatment
by 1 h/night [31]. When we adjusted for this factor,
adherence to treatment was still adequate [32].
From the present investigation, we conclude that
OSAHS patients perform worse on a monotonous simulated
driving test when compared with control subjects. When
evaluating the effects of treatment, adequate OSAHS
management with either OA or CPAP therapy usually
resulted in substantial improvements of simulated driving.
Although our findings suggest a more pronounced effect of
CPAP on simulated driving performance, this phenomenon
is largely explained by the relatively small study groups and
large inter-group variance. Conclusions beyond both treat-
ments improving simulated driving performance are there-
fore not justified. Studies with larger sample sizes that use a
placebo group are warranted to elucidate the specific
differences in effects of OA and CPAP therapy on
simulated driving performance.
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